San Francisco startup Structure Therapeutics can also be working on an oral, as soon as-day-to-day GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June each time a mid-stage study showed average weight loss of about six% and it ideas to get started on A further mid-phase trial to the top of this year—that